Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 27,749 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Not listed Phase 2 Interventional

Topical Bimatoprost in the Treatment of Migraine

NCT03419715
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders
Interventions
Bimatoprost Topical Solution, Control
Drug
Lead sponsor
Manistee Partners
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Cincinnati, Ohio • Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

NCT06280235
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Oceanside, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Not applicable Interventional Results available

Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores

NCT02840240
View directory record Official record
Conditions
Pain
Interventions
Gabapentin enacarbil, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional Results available

Effect of Milnacipran in Chronic Neuropathic Low Back Pain

NCT01225068
View directory record Official record
Conditions
Low Back Pain
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 2 Interventional

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

NCT00108810
View directory record Official record
Conditions
Pain, Osteoarthritis, Knee
Interventions
Transdermal Ketoprofen Patch with CHADD, Placebo transdermal patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Buena Park, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 14, 2026, 1:49 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction

NCT06864884
View directory record Official record
Conditions
Acute Post Operative Pain, Third Molar Extraction Surgery
Interventions
ARC-001, Placebo gel
Drug
Lead sponsor
Arcato Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

NCT06033833
View directory record Official record
Conditions
Asthma
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Stockton, California • Boynton Beach, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

NCT01275248
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Transcept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 4 Interventional Results available

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

NCT01144143
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Infliximab, Placebo, Standard of Care: Methylprednisolone acetate
Drug
Lead sponsor
Herbert Lindsley, MD
Other
Eligibility
35 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259308
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
62
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654374
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Interventions
aleniglipron, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

NCT02930018
View directory record Official record
Conditions
Stroke, Acute
Interventions
Nerinetide (NA-1), 2.6 mg/kg, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 14, 2026, 1:49 AM EDT
Not listed Phase 3 Interventional

Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction

NCT06143787
View directory record Official record
Conditions
Bleeding From Teeth, Bleeding Prophylaxis
Interventions
Tranexamic acid
Drug
Lead sponsor
Hyloris Developments
Industry
Eligibility
18 Years to 99 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Loma Linda, California • Stamford, Connecticut • Millcreek, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 3 Interventional

Perennial Allergic Rhinitis Study In Pediatric Subjects

NCT00108914
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 12 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Costa Mesa, California • Cudahy, California • Long Beach, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

NCT05351047
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants

NCT04366349
View directory record Official record
Conditions
Healthy Volunteers, Asthma
Interventions
melrilimab (GSK3772847) 70 milligram (mg), melrilimab (GSK3772847) 140 milligram (mg), Placebo
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 14, 2026, 1:49 AM EDT
Active, not recruiting Phase 4 Interventional

Long-term Effectiveness of the Antiobesity Medication Phentermine

NCT05176626
View directory record Official record
Conditions
Obesity, Obesity; Drug, Lifestyle, Healthy
Interventions
Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG
Behavioral · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Saint Louis Park, Minnesota • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Not applicable Interventional

Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy

NCT02445378
View directory record Official record
Conditions
Acute Leukemia, Anorexia, Anxiety, Depression, Dyspnea, Insomnia, Nausea, Pain
Interventions
Aromatherapy and Essential Oils, Placebo, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S-Equol in Alzheimer's Disease 2 Trial

NCT03101085
View directory record Official record
Conditions
Alzheimer Disease
Interventions
S-equol and Placebo, Placebo and S-equol
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

NCT00439868
View directory record Official record
Conditions
Depressive Disorder
Interventions
WellbutrinXL, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 14, 2026, 1:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

NCT07133191
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Selatogrel, Matching placebo
Combination Product
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
20 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 1:49 AM EDT
Terminated Phase 2 Interventional Results available

Renal AL Amyloid Involvement and NEOD001

NCT03168906
View directory record Official record
Conditions
Amyloidosis
Interventions
NEOD001, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 14, 2026, 1:49 AM EDT